Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Accumulated Expenses: 2012-2025

Historic Accumulated Expenses for Ptc Therapeutics (PTCT) over the last 8 years, with Sep 2025 value amounting to $49.5 million.

  • Ptc Therapeutics' Accumulated Expenses rose 7.05% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year increase of 7.05%. This contributed to the annual value of $61.6 million for FY2024, which is 16.92% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Accumulated Expenses stood at $49.5 million, which was up 29.34% from $38.2 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Accumulated Expenses ranged from a high of $74.1 million in Q4 2023 and a low of $24.9 million during Q1 2021.
  • Over the past 3 years, Ptc Therapeutics' median Accumulated Expenses value was $46.2 million (recorded in 2024), while the average stood at $48.4 million.
  • In the last 5 years, Ptc Therapeutics' Accumulated Expenses spiked by 52.63% in 2023 and then tumbled by 34.71% in 2024.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Accumulated Expenses stood at $55.7 million in 2021, then grew by 12.45% to $62.7 million in 2022, then grew by 18.26% to $74.1 million in 2023, then declined by 16.92% to $61.6 million in 2024, then grew by 7.05% to $49.5 million in 2025.
  • Its Accumulated Expenses stands at $49.5 million for Q3 2025, versus $38.2 million for Q2 2025 and $32.1 million for Q1 2025.